ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2375

Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?

Burak Kundakci1, Megan Barber2, Ann E. Clarke2, Sindhu Johnson3, Ian Bruce1 and On behalf of the revised SLE organ damage index (SDI) collaborators4, 1Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 2Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4University of Manchester, Manchester, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Damage Index, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The Systemic Lupus International Collaborating Clinics (SLICC), Lupus Foundation of America (LFA), and American College of Rheumatology (ACR) are leading a global initiative to create a revised Systemic Lupus Erythematosus Damage Index (SDI). One limitation of the current SDI is a notable floor effect where most patients score between zero and three, with up to 50% in most cohorts scoring zero.1 Potential ways to address this floor effect include adding items and/or providing more sensitive definitions through describing different grades within the same item. This study aims to report the items suggested for gradation in a revised damage index.

Methods: Item generation began with a comprehensive literature review and an initial Delphi round. Item reduction involved conducting two additional Delphi rounds, where items with a median score of ≤4 out of 9 were excluded. Following this, a 14-member steering committee assessed the remaining items and removed those that did not reflect the damage construct, were excessively rare, or were not feasible to assess. The expert organ domain groups then refined the remaining items, suggesting severity gradations for relevant items. Figure 1 illustrates the stages of item generation and reduction.

Results: The item generation and reduction phases resulted in 45 proposed candidate items for the revised SDI.2 Of these items, organ-specific groups suggested grading for 11 (24.4%) items (Table 1). For example, ischaemic heart disease is proposed to be graded as follows: Grade 1: asymptomatic ischaemia on testing, Grade 2: symptomatic angina with confirmatory tests Grade 3: myocardial infarction (clinical presentation and confirmatory tests) and Grade 4: multiple myocardial infarction and/or coronary artery bypass grafting. Similarly, kidney function impairment is proposed to be graded according to Kidney Disease Improving Global Outcomes (KDIGO) categories of glomerular filtration rate (GFR). Grade 0 -GFR ≥60 mL/min/1.73 m², Grade 1 -GFR 30-59 mL/min/1.73 m², Grade 2 – GFR 15-29 mL/min/1.73 m², and Grade 3 GFR < 15 mL/min/1.73 m².

Conclusion: Grading damage items is possible for 24.4% of proposed items in a new revised damage index. This offers a more detailed and clinically relevant assessment of organ damage in SLE patients. It reflects current evidence based medical practice and is likely to improve sensitivity of the index in SLE populations. Further validation in cohorts and consideration of weighting of grades across clinical organ systems is now underway.

< !  Sutton EJ et al. SLICC damage index: a systematic literature review. Seminars in arthritis and rheumatism. 2013; 43(3):352-361

< !  Kundakci B et al. POS1139 Lupus Damage Index Revision – Item Generation and Reduction Phase. Annals of the Rheumatic Diseases. 2024; 83:1009-1010.

Supporting image 1

Figure 1. Item generation and reduction phases

Supporting image 2

Table 1. Items suggested for gradation in the revised damage index


Disclosures: B. Kundakci: None; M. Barber: AbbVie/Abbott, 2, AstraZeneca, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Sanofi-Genzyme, 2; A. Clarke: AstraZeneca, 2, 5, 6, Bristol Myers Squibb, 2, GSK, 2, 5, 6, Otsuka Pharmaceutical, 1, Roche, 1; S. Johnson: None; I. Bruce: AstraZeneca, GSK and UCB, 6, Genzyme/Sanofi, GSK, Roche, Novartis, Janssen, UCB, 5; O. organ damage index (SDI) collaborators: None.

To cite this abstract in AMA style:

Kundakci B, Barber M, Clarke A, Johnson S, Bruce I, organ damage index (SDI) collaborators O. Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus? [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/can-damage-items-be-graded-according-to-severity-in-a-revised-organ-damage-index-for-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-damage-items-be-graded-according-to-severity-in-a-revised-organ-damage-index-for-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology